67. Polycystic kidney disease Clinical trials / Disease details

Clinical trials : 221 / Drugs : 212 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 151

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02127437 (ClinicalTrials.gov)	September 19, 2014	2/4/2014	Lanreotide In Polycystic Kidney Disease Study	Lanreotide In Polycystic Kidney Disease Study	Autosomal Dominant Polycystic Kidney Disease (ADPKD	Drug: Lanreotide;Drug: saline	Assistance Publique - Hôpitaux de Paris	IPSEN pharmaceutical company, Boulogne-Billancourt, France	Completed	18 Years	N/A	All	159	Phase 3	France
2	NCT01377246 (ClinicalTrials.gov)	May 2011	20/6/2011	Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency	A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO ASSESS THE EFFECTS OF LONG-ACTING SOMATOSTATIN (OCTREOTIDE LAR) THERAPY ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND MODERATE TO SEVERE RENAL INSUFFICIENCY	Autosomal Dominant Polycystic Kidney Disease	Drug: Octreotide -LAR;Other: Saline solution.	Mario Negri Institute for Pharmacological Research	NULL	Completed	18 Years	75 Years	All	100	Phase 3	Italy
3	NCT00309283 (ClinicalTrials.gov)	April 2006	30/3/2006	Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study	Effect of a Long-acting Somatostatin on Disease Progression in Nephropathy Due to Autosomal Dominant Polycystic Kidney Disease: a Long-term Three Year Follow up Study	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Drug: Long-acting somatostatin;Other: Saline solution	Mario Negri Institute for Pharmacological Research	NULL	Completed	18 Years	75 Years	Both	78	Phase 3	Italy